A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients
Debbie S. Deben, Dennis R. Wong(Zuyderland Medisch Centrum), Rob H. Creemers(Zuyderland Medisch Centrum), Mathie P.G. Leers(Zuyderland Medisch Centrum), Arjan J. van Adrichem(University of Helsinki), Roosmarie J.M. Drent(Zuyderland Medisch Centrum), Audrey H. H. Merry(Zuyderland Medisch Centrum), Adriaan A. van Bodegraven(Zuyderland Medisch Centrum)
Cited by 3
Related Papers
Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions
|Cell chemical biology|2017|172
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
|Journal of Crohn s and Colitis|2020|71
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
|Clinical Gastroenterology and Hepatology|2022|51
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
|Pharmaceutics|2023|17
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease
|Journal of Crohn s and Colitis|2022|16